1-7 of 7
Xiaomeng Hu
Close
Sort by
Journal Articles

Hypoimmune, Allogeneic CD22-Directed CAR T Cells That Evade Innate and Adaptive Immune Rejection for the Treatment of Large B Cell Lymphoma Patients That Are Relapsed/Refractory to CD19-Directed CAR T Cell Therapy

Adam Johnson, Hallee Wright, Xiaomeng Hu, Jeremy Kinder, Neal van Hoeven, Ouwen Liang, Brian Granger, Tori Duback, Chris Baldeviano, Sundeep Chandra, Trevor McGill, Boris Gorovits, Shannon Joyce, Sam Crocker, Anna Liang, Carrie Rocca, Jenny Migliaccio, Prasanna Kumar, Vasily Vagin, Kerrie Enger, Chi Young, Andrew McAlister, Sonja Schrepfer, Terry J. Fry
Journal: Blood
Blood (2023) 142 (Supplement 1): 3437.
https://doi.org/10.1182/blood-2023-187096
Published: 2023
Journal Articles

Development of a Novel, Allogeneic GPRC5D-Directed CAR for Treatment of Multiple Myeloma Patients

Jeremy Kinder, Chanel Athena Estrada, Brian Granger, Allison O'Rourke, Ouwen Liang, Aaron Lampano, Garrett Zipp, Vandana Chaturvedi, Xiaomeng Hu, Chi Young, Neal van Hoeven, Sonja Schrepfer, Terry J. Fry
Journal: Blood
Blood (2023) 142 (Supplement 1): 3290.
https://doi.org/10.1182/blood-2023-189665
Published: 2023
Journal Articles

Phase 1 Study of SC291, a Hypoimmune, Allogeneic CD19-Directed CAR T Cell Therapy for Relapsed/Refractory B-Cell Malignancies (ARDENT) - Initial Clinical Data

Sattva S. Neelapu, L. Elizabeth Budde, Joseph P McGuirk, Saurabh Dahiya, Abhinav Deol, Philip A. Thompson, Nitin Jain, Matthew A Lunning, Xiaomeng Hu, Boris Gorovits, Danielle Quarles, Barbara Metallo, Meghan Flaherty, Weidong Zhang, Hosein Kouros-Mehr, Terry J. Fry, Sonja Schrepfer
Journal: Blood
Blood (2023) 142 (Supplement 1): 6852.
https://doi.org/10.1182/blood-2023-179441
Published: 2023
Journal Articles

BCMA-Targeted, Hypoimmune Allogeneic CAR T Cells Exhibit Potent Anti-Tumor Activity Together with the Ability to Evade Innate and Adaptive Immune Rejection in Pre-Clinical Tumor Models

Jeremy M. Kinder, Chanel Athena-Estrada, Danyal Malik, Xiaomeng Hu, Meghan Lamba, Chi Young, Neal Van Hoeven, Brian Granger, Vandana Chaturvedi, Ouwen Liang, Jesus Moreno, Aaron Lampano, Garrett Zipp, Adam Johnson, Terry Fry, Sonja Schrepfer, Aaron Foster
Journal: Blood
Blood (2022) 140 (Supplement 1): 7120–7121.
https://doi.org/10.1182/blood-2022-166845
Published: 2022
Journal Articles

Engineered Hypoimmune CAR T Cells Provide Lasting Tumor Control in Fully Immunocompetent Allogeneic Humanized Mice

Xiaomeng Hu, Pascal Beauchesne, Karl Manner, Corie Gattis, Priscilla Ngo, Rowena De Jesus, Chi Young, Frank Wells, Lindong Weng, Kathy White, William E Dowdle, Aaron Foster, Terry Fry, Sonja Schrepfer
Journal: Blood
Blood (2022) 140 (Supplement 1): 1173–1175.
https://doi.org/10.1182/blood-2022-167943
Published: 2022
Journal Articles

A Dual-Antigen Targeting, Hypoimmune Allogeneic CAR T to Evade Innate and Adaptive Immune Rejection and Overcome Antigen Escape

Adam Johnson, Hallee Wright, Xiaomeng Hu, Neal van Hoeven, PhD, Brian Granger, Ouwen Liang, Jesus Moreno, Meghan Lamba, Chi Young, Andrew McAlister, Terry J. Fry, Sonja Schrepfer, Aaron Foster
Journal: Blood
Blood (2022) 140 (Supplement 1): 4552–4553.
https://doi.org/10.1182/blood-2022-168251
Published: 2022
Journal Articles

Engineered Hypoimmune Allogeneic CAR T Cells Exhibit Innate and Adaptive Immune Evasion Even after Sensitization in Humanized Mice and Retain Potent Anti-Tumor Activity

Xiaomeng Hu, Mo Dao, Kathy White, Corie Gattis, Ryan Clarke, Sam Landry, Ron Basco, Eleonore Tham, Andrew Tucker, Emily Luo, Christopher Bandoro, Elaine Chu, Chi Young, Aaron E. Foster, William E Dowdle, Edward J Rebar, Terry J. Fry, Sonja Schrepfer
Journal: Blood
Blood (2021) 138 (Supplement 1): 1690.
https://doi.org/10.1182/blood-2021-150021
Published: 2021